Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $256,437.50 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 6,250 shares of the firm's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $41.03, for a total transaction of $256,437.50. Following the completion of the transaction, the insider now owns 169,721 shares in the company, valued at $6,963,652.63. The trade was a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Timothy Rolph also recently made the following trade(s):

• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total value of $224,250.00.
• On Wednesday, March 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.53, for a total transaction of $556,625.00.
• On Wednesday, February 5th, Timothy Rolph sold 18,750 shares of Akero Therapeutics stock. The shares were sold at an average price of $56.51, for a total transaction of $1,059,562.50.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO traded down $0.44 during midday trading on Friday, reaching $44.87. 1,212,166 shares of the company traded hands, compared to its average volume of 879,941. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock's 50-day simple moving average is $41.66 and its 200-day simple moving average is $37.07. The firm has a market cap of $3.58 billion, a PE ratio of -11.97 and a beta of -0.12.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, equities analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. HC Wainwright boosted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Canaccord Genuity Group raised their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, UBS Group raised their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $76.29.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company's stock worth $3,662,000 after purchasing an additional 71,652 shares during the last quarter. Exome Asset Management LLC acquired a new position in shares of Akero Therapeutics during the third quarter valued at $2,212,000. SG Americas Securities LLC boosted its holdings in Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock valued at $16,636,000 after acquiring an additional 583,486 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Akero Therapeutics by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company's stock valued at $412,000 after acquiring an additional 1,446 shares during the last quarter. Finally, abrdn plc increased its position in Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company's stock worth $7,505,000 after purchasing an additional 146,424 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.